Ignite Creation Date:
2024-05-05 @ 11:54 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00169598
Status:
UNKNOWN
Last Update Posted:
2007-04-27
First Post:
2005-09-13
Brief Title:
Remission Evaluation Before Intensified Treatment in Lymphoma Impact of Positron Emission Tomography PET Using Fluorine-18-Floro-Deoxyglucose FDG in the Therapeutic Prescription Medico-Economic Randomised Study
Sponsor:
Hospices Civils de Lyon
Organization:
Hospices Civils de Lyon
Study Overview
Official Title:
Remission Evaluation Before Intensified Treatment in Lymphoma Impact of Positron Emission Tomography PET Using Fluorine-18-Floro-Deoxyglucose FDG in the Therapeutic Prescription Medico-Economic Randomised Study
Status:
UNKNOWN
Status Verified Date:
2007-04
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TEPELY
Brief Summary:
This randomised study aimed at evaluating the medical and economical impact of positron emission tomography PET using fluorine-18-fluoro-deoxyglucose FDG in the therapeutic prescription in patients with Hodgkins lymphoma or with large B and P cell non-Hodgkins lymphoma The median progression free survival the costs and the quality of life are compared between two groups Group 1 the results of conventional staging and of the PET are known before stem cell transplantation Group 2 only the results of conventional staging before stem cell transplantation are known before stem cell transplantation
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None